G-SPECT nominated for Accenture Innovation Award

View this email in your browser

MILabs Newsletter September 2017

G-SPECT nominated for Accenture Innovation Award

Recently G-SPECT received the WMIS Innovation of the Year Award. This game changing clinical scanner has now been nominated for the Accenture Innovation Award.

The G-SPECT offers unprecedented resolution, sensitivity and speed, with an isotropic resolution of 3.5mm, whereas current clinical solutions deliver images with a resolution of ~10mm.

The G-SPECT is expected to dramatically increase patient throughput, reduce patient dose by a factor of over 10, enable multiple dynamic scans and improve diagnostic accuracy.

Vote for this ground-breaking technology today!

G-SPECT is in the phase of finalization and documentation in order to obtain CE and FDA clearance for commercial introduction, which is expected in the coming year.

Click Here – Vote today!

See us at WMIC 2017 in Philadelphia, PA – Booth 302
September 13-16

Pushing the limits of molecular imaging.
Learn more about MILabs’ Series 5 multi-modality PET/SPECT/OI/CT platforms offering <0.15 mm SPECT resolution and <0.6 mm PET resolution. The Series 5 systems feature hybrid nuclear and optical imaging, with unmatched morphological 4D CT capabilities.

Diagnosing viral infection and treatment response with high-resolution whole-body MILabs PET/CT

Acute infections caused by dengue virus (DENV) and other members of the flavivirus genus, such as Zika virus, Japanese encephalitis virus, West Nile virus, and yellow fever virus, pose a significant threat to global public health. As the global burden of diseases such as dengue continues to rise, with nearly 400 million infections each year and more than two-thirds of the world’s population at risk of infection, therapeutic interventions are urgently required (1). Unfortunately, there have been no biomarkers that can sensitively distinguish viral load reduction due to innate cellular antiviral response from the viral load reduction due to antiviral drug-mediated mechanisms, thus significantly hampering the development of new antiviral drugs (2). Therefore, there is an urgent need to develop translational clinical platforms that will allow further understanding of disease pathophysiology.

In this scientific publication, researchers at Duke-NUS in Singapore demonstrate that high resolution whole-body PET/CT imaging of 18F-FDG with MILabs VECTor PET/SPECT/CT enables the sensitive detection of inflammatory disease foci in dengue-infected mice and that 18F-FDG can be used as a biomarker for quantifying disease response to treatment.

18F-FDG as an inflammation biomarker for imaging dengue virus infection
and treatment response
Chacko et al., JCI Insight. 2(9):e93474. (2017)

Increased inflammation in the spleen, and small and large intestines of dengue-infected mice can be observed using positron emission tomography (PET), paired with the glucose metabolism probe, fluorodeoxyglucose (FDG) [middle], with the inflammation subsiding after antivirals were given [right]

Summary

MILabs’ high-resolution VECTor PET/SPECT/CT system is used to:

Image the whole-body of mice at sub-mm PET resolution in order to quantify 18F-FDG uptake in foci in the abdomen, including the S.Int., L.Int., spleen, and mesentery.
Monitor DENV-mediated inflammation in vivo and assess the efficacy of novel therapeutic compounds that can directly target the major tissues involved in dengue pathogenesis.
Demonstrate for the first time that the quantifiable reduction in intestinal 18F-FDG uptake by PET/CT imaging can be used to non-invasively and robustly define inflammation reduction as a surrogate endpoint for drug efficacy during preclinical development and clinical validation.
Show a significant temporal trend in 18F-FDG uptake in intestines and selected tissues and that sub-mm resolution PET robustly differentiated treatment-naive groups from drug-treated infected mouse groups.
Illustrate that high resolution whole-body PET/CT imaging of 18F-FDG may have a profound effect on reducing the high costs of drug discovery for emerging infectious diseases through reducing trial size and fast tracking of the drug development process.

Link to Publication

Related Publications
1. Guzman MG, Harris E. Dengue. Lancet. 2015; 385(9966):453–465.
2. Sung C, et al. Extended Evaluation of Virological, Immunological and Pharmacokinetic Endpoints of CELADEN: A Randomized, Placebo-Controlled Trial of Celgosivir in Dengue Fever Patients. PLoS Negl Trop Dis. 2016;10(8): e0004851.

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

G-SPECT nominated for Accenture Innovation Award

In This Issue

Contact Us

Keep Up With Us